1 August 2026
In plain English
Medicare's new programme covering weight-loss drugs like Ozempic (called GLP-1s) is a month old and has published no enrolment number. We found something better. An independent analysis puts the pool of people who can actually qualify at about 3.8 million — not the 14 million our own forecast assumed. The US Medicare agency expected 800,000 to 1.2 million people to try filling a prescription in July alone.
We also found a fault in our own prediction. It promises to check the answer against Medicare's prescription records, but this programme was deliberately built to run outside them. As written, it may be unscoreable. Flagged for repair.
Elsewhere: nine days after a US advisory panel backed six experimental drugs called peptides (short protein fragments used for recovery and longevity), the federal rulebook still shows nothing filed. Nothing is legally on sale.
Signal detail
· flagged, fifth consecutive run Two corrections landed, pulling opposite ways. The Historian re-read the forecast's own note and found its denominator wrong: it reasons from 14M eligible, but KFF's claims-based analysis (2026-06-29, fetched at primary source today) puts Bridge-eligible Part D enrollees at 3.8M, against a CMS year-one estimate of 3.4M. The 13M-plus figure is the broader Medicare obesity-and-overweight population — a different set. The 1M bar is therefore roughly 26% of eligible, not 7%, making the forecast harder to falsify. Against that, the Skeptic's central claim was upgraded from trade-press assertion to corroborated agency figure: CMS projected 800,000–1.2M July fill attempts against that same 3.4M, i.e. the agency models a 24–35% month-one attempt rate. Attempts are not enrollees — prior authorisation with clinician attestation sits between — but the agency's own model points above the threshold. The second effect is larger, so the Bayesian takes 0.66 → 0.63. Historian 0.80 against Skeptic 0.45: divergence 0.35, wider than yesterday rather than narrower. Day 32, still no enrollment figure anywhere. The bigger finding is not the probability. This forecast names "official CMS Part D enrollment data" as its resolution source. KFF confirms the Bridge operates outside the Part D benefit and payment system by design. The named source structurally cannot report the forecast quantity — unresolvable as written on 2026-12-31. See §6.
· Two offsetting signals. Negative: the Federal Register carries zero bulk-drug-substances documents since 2026-07-01 (count 0, verified today), so nine days past the vote the compliant path has not opened, and counsel puts notice-and-comment at six to twelve months. Positive: Leerink models peptide sales near $440M, ~15% of the Hims 2026 revenue midpoint, inside a $2.2B telehealth peptide market with Hims near 20% share — raising the pressure to say something concrete on the Aug 10 call, nine days out. These cancel, because the forecast asks for a public launch, not a lawful or durable one, and the Feb 2026 launch-then-retreat pattern satisfies it either way.
· Zero bulk-drug-substances documents means no legal 503A supply to hang an affiliate programme on in five months, and the networks will not onboard pre-rulemaking gray-market vendors. Confirming an insight is not repricing it. But the uncomfortable first-party reading: Katalys payout fell $450 → $300 while clicks rose 45%, GSC impressions −20%. A ratio forecast stays true when its numerator is zero regardless of the base. Routed to §6 rather than repriced.
· No new evidence. A sweep for NYT, WSJ, CNN and NPR returned nothing newer than WaPo July 24; the only fresh Federal Register peptide items since are two NIH invention-licensing notices and one guidance notice, none of them safety. 85 → 84 on mild decay. Augur pick. In yesterday's Federal Register pull, unremarked at the time: document 2026-14692, published 2026-07-21 — two days before the vote — a foreign-trade-zone production notification from PolyPeptide Laboratories Inc. (Peptides), Torrance, California. A contract peptide manufacturer filing for FTZ capacity in the week the committee sat. It may be routine; FTZ filings have long lead times. But manufacturing capacity positioning immediately ahead of a regulatory decision is the class of signal that appears before a supply chain exists, from an assignee outside the crowd this log watches. Noting it, claiming nothing. New forecast candidate. Counsel reports a second advisory-committee meeting on five further peptides expected February 2027 — the peptide story is a cadence, not a single event. Barque still has no forecast on the binding FDA decision following the July vote, a gap the 2026-07-26 resolution note flagged. Proposed for operator approval; Ra does not auto-add.
Resolutions & upcoming
No overdue forecasts. All four pending rows resolve 2026-12-31 or later; nothing resolves inside 14 days. Nothing resolved today.
One resolution decision is open and ageing — day 8. The council has flagged since 2026-07-24 that the WaPo investigation "Peptide boom has states scrambling to protect consumers" may already satisfy `peptide-safety-incident`. It is a top-5 outlet running a major investigation about peptide injection risk. Whether it counts turns on whether "a major feature on peptide injuries, contamination, or deaths" is satisfied by a piece framed on regulatory failure. That is a judgement call only the operator can make, and it has now sat unanswered for eight days while the council logs a probability for an event that may have already happened.
How Barque got smarter today
- The denominator nobody checked. A KFF analysis published 2026-06-29 reset the eligible pool for `medicare-glp1-bridge-uptake` from 14M to 3.8M, and it sat uncited through fourteen Ra runs while the council argued about the numerator. The failure mode is specific: once a forecast's note contains a number, the council treats it as given and re-derives only the news around it. New standing check — re-verify a forecast's own stated base quantities periodically, not just the evidence that moves them.
- A forecast can be well-calibrated and still unscoreable. Fourteen runs of probability work on a question whose answer may never appear where the forecast says to look. I audited the other three pending rows: `hims-peptide-launch` (observable launch) and `peptide-affiliate-share` (internal Katalys data) are fine. `peptide-safety-incident` has a related but different flaw — a judgement-dependent threshold ("major feature") with no operator rubric, which is exactly why it has sat eight days. Two distinct repairs, both in §6.
- Tier-2 Reddit is not a WebFetch problem. Six briefs have logged "Reddit blocked" as though it were a sandbox artifact. I pointed agent-fetch.yml at r/peptides today: HTTP 403 from the GitHub runner too, carrying Reddit's own text asking for a login or developer token. The gap is Reddit blocking unauthenticated datacenter traffic; the fix is an OAuth token in repo secrets, not another fetch path. Six runs of a mislabelled blocker, now correctly labelled.
- ra_log citations are not replayable. The log records Federal Register queries with literal square brackets; curl rejects that form (exit 3, bad range in URL), costing a wasted runner call today before I re-encoded them. I checked yesterday's run logs first: the underlying fetches were real and returned 200, so this is a formatting defect, not a sourcing one. Worth fixing anyway — a citation you cannot replay is weaker than one you can.
- Voice calibration, honest version. Three of four forecasts held at delta 0. Two of those holds are principled. But a council that holds three-quarters of its book daily should be suspicious of itself, and the single move that did happen came from re-reading a five-week-old document rather than from any of today's news. The Historian and the Augur earned their places today. The Bayesian mostly did not.